[11C]Erlotinib in non-small cell lung cancer patients with and without erlotinib therapy.
- Conditions
- on-small cell lung cancer NSCLCNiet-kleincellig longkanker
- Registration Number
- NL-OMON28948
- Lead Sponsor
- VU University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Patients with NSCLC, planned to receive erlotinib for therapy will be included in this study. Ten evaluable patients are needed. It is expected that this number of patients will be recruited within 1 year.
1. Patients age: Between 18 and 70 years;
Exclusion Criteria
1. Claustrophobia;
2. Pregnant or lactating patients;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy.
- Secondary Outcome Measures
Name Time Method Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and to explore the usefulness of static whole body images. Also, to validate image derived input function (IDIF) against continuous arterial sampling.